Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Since Nov. 1, South Carolina has recorded 86 reported cases of the contagious disease. State Epidemiologist Linda Bell said Monday that's more than four times what state officials normally expect to see. Over the last 10 years, South Carolina averaged 19 reported cases of hepatitis A annually. Most of the new cases have occurred in Aiken County, and almost half of all cases involve individuals who reported drug use, Bell said. Still, the general population needn't be overly concerned, she said. "But we are seeing cases higher that what we expect to see," Bell said. "And so it's important for us to do our prevention efforts early to reach those high-risk groups, get them vaccinated ... so that we can prevent" a severe outbreak. The State reports the Department of Health and Environmental Control is offering no-cost vaccines to high risk groups including drug users, homeless, formerly incarcerated and sexually-active gay men. Additionally, health officials recommend all children get two doses of the vaccine as part of their immunization schedule. Of the 86 reported cases in South Carolina, 59 have led to hospitalization and one resulted in death, the DHEC said. Hepatitis is a disease characterized by inflammation of the liver. It comes in many forms, including hepatitis A, B and C. As a result, individuals with chronic liver disease, like cirrhosis, are at increased risk of complications if infected and should be vaccinated. The virus-borne infection can be prevented by vaccination and is usually transmitted person-to-person through consumption of contaminated food or water, according to the U.S. Centers for Disease Control and Prevention. Antibodies produced in response to hepatitis A infection last for life and protect against reinfection. Infection usually results in sickness in two to six weeks after exposure. Symptoms include fatigue, loss of appetite, stomach pain, nausea, and yellowing of the eyes and skin. Symptoms usually resolve within two months of infection, according to the CDC. State public health officials in February declared an outbreak in Aiken County after an employee at a second restaurant in Aiken tested positive for the virus, the DHEC said. Bell, though, stressed transmission by food or beverage is uncommon. "Most transmission in the United States is through person-to-person contact," Bell said. "Good hygiene - diligently washing your hands - is a good way to prevent hepatitis A, as well as not sharing personal items," including drug equipment, she said, adding the state has received reports of hepatitis A from people using various drugs, "everything from marijuana to meth." Residents can schedule an appointment for a vaccination at their local health department by calling 855-472-3432 or going to http://bit.ly/2HhEsM8 . ___ Information from: The State, http://www.thestate.com
Example Output: South Carolina declares hepatitis outbreak.

Example Input: Igor is a 13-year old tiger living in the zoo in the southern Hungarian town of Szeged. It has been suffering from hip joint pains for years. The treatment, used more widely on humans than animals, cures injured joints with tissue taken from patients' own fatty tissue, which contains regenerative stem cells, doctors said. These are injected back into the ailing joints. "The essence of stem-cell treatment is that we can achieve an improvement in the quality of life of patients who cannot be helped by operations or medical treatment," said Robert Gippert, the veterinarian who operated on Igor's hip. "Just like in humans, the worn out joint of Igor the tiger will heal due to the regenerative and self-healing effects of stem cells, without the use of external materials," he added. The sedated tiger was lying peacefully on its side on the operating table, with its big paws sticking out from below a green blanket. After Igor wakes up, it could take two to three weeks before vets can judge the improvement in its movement.
Example Output: Igor the Siberian tiger gets stem-cell hip treatment in Hungary.

Example Input: Hooray! Unlike the WebMD story, this story includes cost information. "The price for IBS treatment hasn't been determined, he said. But the price listed at Drugstore.com suggests it's not cheap, with a two-week supply of the dosage used in the study costing $910, or about $21 a pill." By providing the price and actually showing readers (and other reporters) the source for the price, the story puts the antibiotic treatment into perspective and goes part of the way toward helping readers judge how cost-effective this treatment may be. Unlike the WebMD story, which took too long to present any of the data, this story attempts to quantify the benefits in the second sentence. "In two large studies, 41 percent of the patients who took the antibiotic rifaximin said their symptoms substantially improved, compared to 32 percent of those who got fake pills. Their relief lasted for up to 10 weeks." The story makes no mention of harms other than antibiotic resistance. Instead, the story says the drug "also been safely used elsewhere for more than two decades." But readers should be told explicitly what side effects were found in the study. The story adequately addresses the number of patients studied, the duration of study and the study endpoints. The story does not engage in disease-mongering. It says that IBS is "a poorly understood and painful condition that especially afflicts younger women" and says that IBS affect as many as 1 in 5 Americans." Better than the WebMD story on this count as well, AP explains that the non-constipation form of IBS is "the most common form." The only researchers quoted in the story are researchers who do drug-company-funded research on IBS drugs. The lead author is identified this way: "Dr. Mark Pimentel, of Cedars-Sinai Medical Center in Los Angeles," and only much later does it say, "The studies were paid for by the Salix, based in Raleigh, N.C. Some of the researchers were Salix employees and others had received consulting and other fees from the company. Cedars-Sinai holds a patent on the use of rifaximin for irritable bowel syndrome." The story should have said clearly, as the WebMD story did, that Pimentel serves as a Salix consultant and sits on its scientific advisory board. The story also quotes Dr. Jan Tack, "ofthe University of Leuven in Belgium." It makes no mention of the detail noted in the WebMD story: that Tack has worked as a scientific advisor to companies evaluating IBS treatments. The final quarter of the story is devoted toAmy McMahon, "who developed the disorder about four years ago." It says, "She tried a variety of treatments, changed her diet, and saw a number of specialists before Pimentel prescribed the antibiotic about a year later. "I felt remarkably better" after one treatment, said McMahon. So here you have a drug-company funded researcher providing a success-story-patient for a quote. The story could have included other patients who saw no relief or no patients at all. This skews the entire perspective of the story. A more representative picture would have been presented by including one of the vast majority who saw no improvement from the antibiotic. Slightly better than the WebMD story. It says, "What causes the disorder has been a mystery; sensitivity to certain foods or stress are among the theories. Patients are typically told to change their diet, reduce stress and take medicines or fiber supplements to ease symptoms." There is no quantitative statement about relative effectiveness of the existing approaches, but they are mentioned and it is clear that symptom reduction is the best that can be offered. The story explains that: "In the U.S., rifaximin is approved for traveler's diarrhea and for a complication of liver disease. Salix Pharmaceuticals, which markets rifaximin under the name Xifaxan in the U.S., is seeking to expand its use to IBS. A decision from the Food and Drug Administration is expected in March, said William Forbes, executive vice president and chief development officer for Salix." Taking predictions from a company exec about when the FDA might act would not result in a good batting average over time. This story, at least, quoted the author of an accompanying editorial saying that he thought the treatment was novel. The story does not rely on a news release.
Example Output:
Antibiotic eases common stomach pain, studies find